Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Acquisitions & Divestments (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $61.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 14.11% to $61.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.8 million, a 36.39% decrease, with the full-year FY2025 number at $252.8 million, down 36.39% from a year prior.
  • Change in Acquisitions & Divestments was $61.8 million for Q4 2025 at Caribou Biosciences, down from $68.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $120.7 million in Q3 2024 to a low of $39.3 million in Q1 2022.
  • A 4-year average of $77.6 million and a median of $70.2 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 151.06% in 2023, then plummeted 47.43% in 2025.
  • Caribou Biosciences' Change in Acquisitions & Divestments stood at $89.7 million in 2022, then crashed by 38.72% to $55.0 million in 2023, then soared by 30.81% to $71.9 million in 2024, then dropped by 14.11% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Change in Acquisitions & Divestments are $61.8 million (Q4 2025), $68.4 million (Q3 2025), and $56.7 million (Q2 2025).